I N T R O D U C T I O N
Nephrolithiasis is a worldwide health care problem with a current lifetime risk of $18.8% in men and $9.4% in women in Western civilizations [1] . In all, 80-90% of stones are composed of calcium oxalate, calcium phosphate or a mixture of both. Hypercalciuria is the most frequent metabolic abnormality encountered in idiopathic calcium stone formers (SF) [2] . Supersaturation of urinary calcium oxalate and calcium phosphate are two of the major driving forces for calcium stone formation. Although many inherited and acquired systemic diseases underlie calcium stone formation, most stones are designated broadly as idiopathic by exclusion [3] . The prevalence of a renal phosphate leak, i.e. hypophosphataemia in conjunction with inappropriately low renal tubular phosphate reabsorption, has been reported to be as high as 53% in recurrent SF, but also present, though much less prevalent, in healthy individuals [4] [5] [6] [7] [8] . Hypophosphataemia-stimulated 1,25(OH) 2 D with secondary augmentation of intestinal calcium absorption has been postulated to cause hypercalciuria (absorptive hypercalciuria type III) in a subgroup of calcium SFs [7, [9] [10] [11] . However, the evidence supporting such a mechanism has been inconclusive. With the exception of one study [4] , no differences in urinary calcium excretion or 1,25(OH) 2 D levels were detected between SFs with and without renal phosphate leak [7, 8, 12] . Compared with healthy non-stone-forming controls, 1,25(OH) 2 D levels have been reported as increased [4] or unchanged [12, 13] in SFs with renal phosphate leak.
The mechanisms responsible for renal phosphate leak in idiopathic SFs remain unclear. A previous study suggested that the renal phosphate leak was closely linked to the renal stone burden at the time of metabolic work-up [6] . In contrast, more recent data suggest that the primary abnormality encountered in SFs with renal phosphate leak is either a frankly elevated or inappropriately normal level of FGF23 [12] . The latter was proposed to be partially caused by an allelic variant of the FGF23 gene (c.C716T; p.T239M) that results in higher FGF23 secretion and increased activation of the FGF receptor/extracellular signal-regulated kinase signalling pathway [13] .
Thus the phenotype of SFs with renal phosphate leak remains poorly defined at the moment and the role of potential confounders [age, sex, body mass index (BMI), renal function, comorbidities] largely unexplored. Furthermore, the association of renal phosphate leak with stone composition, stone frequency and BMD has not been studied, causing significant impediments for clinicians to recognize and understand this disorder. To address these issues, we conducted a cross-sectional analysis in our cohort of idiopathic calcium SFs.
M A T E R I A L S A N D M E T H O D S

Study population and protocol
The study was conducted with patients recruited at the Division of Nephrology and Hypertension at the Bern University Hospital, Bern, Switzerland with approval from the Ethical Committee of the Kanton Bern. All participants provided written informed consent and the study was conducted in accordance with the Declaration of Helsinki. Patients were seen at the division between March 2004 and June 2016. Inclusion criteria for this study were informed consent, age !8 years and at least one calcium stone episode. A calcium stone was defined as at least one stone analysis with a calcium-containing stone or radiopaque stone by plain abdominal X-ray or a >500 Hounsfield unit stone on computed tomography. Patients were excluded from the study analysis based on the following criteria: primary hyperparathyroidism or history of parathyroidectomy; sarcoidosis; primary or enteric hyperoxaluria; chronic pancreatitis; chronic diarrhoea; complete distal renal tubular acidosis (dRTA); known cystinuria or elevated 24-h cystine excretion; uric acid nephrolithiasis; chronic liver disease or >3-fold elevated liver enzymes; BMI <16 or >40 kg/m 2 ; history of anorexia nervosa or bulimia; active malignant diseases; pregnancy during the study visit; history of solid organ transplantation; hypocortisolism; hyperthyroidism with a TSH <0.1 mU/L; total plasma calcium >2.5 mmol/L with parathyroid hormone (PTH) >65 pg/mL or administration of over-the-counter or prescribed calcium and/or vitamin D supplements, phosphate, bisphosphonates, cinacalcet, denusomab, teriparatide, systemic glucocorticoids or mineralocorticoids, antiepileptics, carboanhydrase inhibitors or diuretics. All variables employed for study analyses were verified by manual review of the original patient charts by N.A.D., D.L., L.S., C.M. and D.G.F. In the final analysis, 555 SFs were included.
Data collection and measurements
Patients collected two 24-h urine samples on a random outpatient diet and a spot urine and a fasting blood draw were performed in the morning after the second 24-h urine collection. All blood parameters were determined from the same blood draw. Plasma FGF23 was measured at the laboratory of TECOmedical AG (Sissach, Switzerland) by the second generation C-terminal assay (Immutopics, San Clemente, CA, USA) with plasma samples frozen at the time of sampling and stored at À80 C. All other urine and blood analyses were performed at the Central Laboratory of the Bern University Hospital as single measurements immediately after sampling. Assay characteristics for the measurements of FGF23, PTH, 25(OH)D and 1,25(OH) 2 D were recently described [14] . The glomerular filtration rate (GFR) was estimated by the creatinine-based Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 2009 equation [15] . Urinary creatinine excretion was used as the criterion for completeness of 24-h urine collections in individuals with normal renal function [16, 17] . Percentiles 2.5 and 97.5 of the 24-h creatinine excretion were calculated for each 24-h urine collection using recently published a linear regression model [18] . Completeness of 24-h urine collections was assumed for each subject if the total 24-h creatinine excretion was within percentiles 2.5 and 97.5. The mean value of both 24-h urine collections was used for the calculation of 24-h urinary excretions.
Corrected plasma calcium was calculated by the formula Tubular maximum reabsorption of phosphorus per glomerular filtration rate (TmP/GFR in mmol/L) was calculated with the algorithm derived by Kenny and Glen [19, 20] . If TRP was 86%, then the formula TmP/GFR (mmol/l) ¼ TRP Â plasma phosphate (mmol/L) was used. If TRP was >86%, then the formula
was used. Both TRP and TmP/GFR were calculated using 24-h urine samples. Diabetes was defined as reported, treated, fasting glycaemia !7 mmol/L (!126.13 mg/ dL) or random glycaemia !11.1 mmol/L (!200 mg/dL). Hypertension was defined as reported, treated, a mean systolic blood pressure !140 mmHg or a mean diastolic blood pressure !90 mmHg. Osteodensitometry was performed at the Department of Osteoporosis at the University Hospital of Bern, Switzerland at the time of biochemical work-up by dual-energy X-ray absorptiometry (DEXA; Hologic QDR 4500A, Hologic, Bedford, MA, USA) at the lumbar spine, the non-dominant femoral neck, the proximal femur and the distal tibia diaphysis and epiphysis as described [21, 22] .
Statistical analysis
All statistical analyses were conducted using R software, version 3.2.2 (R Project for Statistical Computing, Vienna, Austria) [23] . The shape of the distribution of each continuous variable was visually inspected and transformations were applied where appropriate to ensure normality for statistical analyses. All statistical tests were two-sided and a P-value <0.05 was considered statistically significant. To estimate associations of renal phosphate handling as a continuous phenotype, i.e. TmP/GFR, with baseline characteristics, laboratory parameters, kidney stone and bone turnover parameters, we applied univariable mixed effects linear and logistic regression analyses. Due to the physiological seasonal variation of vitamin D levels, the calendar day of blood sampling was taken into account as a random effect in all mixed effects regression models. Independent associations of urinary phosphate leak with variables of interest were analysed by multivariable mixed effects linear and logistic regression containing sex, age, BMI, GFR, diabetes mellitus (yes or no) and hypertension (yes or no). Multivariable regression models were visualized using the R package visreg, which shows the relationship between TmP/GFR and characteristics of interest while holding the effect of all other covariables in the model constant [24] . For visualization, regression models were re-created without including a random effect.
R E S U L T S
Characteristics of study population
We included adult SFs with idiopathic calcium stones in the study. A total of 555 SFs met the inclusion criteria (age !18 years, written informed consent, at least one episode with a calcium-containing kidney stone) and had no exclusion criterion (for details see 'Materials and methods').
Demographic and anthropometric characteristics, stone analyses and bone density measurements of study participants are shown in Table 1 . The majority of patients were male (77%), the median age was 43 years and most patients had recurrent stone disease (82%). DEXA-based bone density measurements were available in 423 of 555 patients (76.2%). Blood and urinary parameters of participants are depicted in Table 2 . The distribution of TmP/GFR in our cohort of calcareous SFs is shown in Figure 1 .
Association analyses
Renal phosphate handling in SFs was assessed by the ratio of tubular maximum reabsorption of phosphate to glomerular filtration rate (TmP/GFR). We first performed the association analyses by mixed effects linear regression with TmP/GFR as the outcome variable and baseline characteristics and blood and urine parameters as predictor variables (Table 3 ). In both univariable and multivariable analyses, calendar day of blood sampling was taken into account as a random effect. Multivariable analyses were adjusted for the covariables age, sex, BMI, GFR, diabetes and hypertension. Male sex (b ¼ À0.06, P < 0.001) and arterial hypertension (b ¼ À0.05, P < 0.01) were found to be inversely associated with TmP/GFR in multivariable analyses. Consistent with previous reports, we found a positive association of TmP/GFR with GFR (b ¼ 0.0013, P ¼ 0.021). There was a strong negative association of PTH (b ¼ À0.002, P < 0.001) and a strong positive association of 25(OH)D The number (n) of participants is indicated for each characteristic. Categorical variables are described by percentage and continuous variables are described by their mean 6 SD or median (25th-75th percentile).
Phosphate leak and kidney stones (b ¼ 0.001, P < 0.01) with TmP/GFR. Given the fact that vitamin D status strongly influences PTH secretion, we performed a second multivariable analysis where the association of PTH with TmP/GFR was additionally adjusted for 25(OH)D levels. As shown in Table 4 , adjusting for 25(OH)D greatly weakened the association of PTH with TmP/GFR to borderline significance (b ¼ À0.001, P ¼ 0.037).
In multivariable analyses we also observed a weak positive correlation of 1,25(OH) 2 D (b ¼ 0.0004, P < 0.05) with TmP/ GFR, but no association was found for FGF23 (b <0 We next performed association analyses with TmP/GFR as the predictor variable and kidney stone history, stone analysis and bone parameters as outcome variables (Table 4) . After multivariable adjustment, renal phosphate leak (i.e. a low TmP/ GFR) was associated with a higher frequency of positive family history of renal stone disease [odds ratio (OR) 0.3, P < 0.05] and with a significantly increased likelihood for younger onset of a first stone event (OR 8.2, P < 0.01). However, we observed no significant association of TmP/GFR with stone recurrence frequency. Interestingly, renal phosphate leak (low TmP/GFR) was associated with an increased risk for brushite-containing stones (OR 0.006, P < 0.01) with a concomitant reduced risk for calcium oxalate-containing stones (OR 219, P < 0.01). BMD measured by DEXA at the lumbar spine, femoral neck, tibia diaphysis and epiphysis as well as the bone turnover marker alkaline phosphatase did not reveal a significant association with TmP/GFR. Figure 3 shows again visualization of multivariable regression models for the association of TmP/ GFR with family history of stone disease, age of first stone event and the probability of calcium oxalate-, calcium phosphate-, apatite-or brushite-containing stones.
D I S C U S S I O N
Classically, SFs are dichotomized with respect to renal phosphate handling [4-8, 12, 25] . The analysis of our cohort of 555 idiopathic calcium SFs demonstrates that TmP/GFR does not have a bimodal distribution but rather is a continuous trait, which is compatible with a previous study [4] . For our association analyses, we choose to treat renal phosphate handling, i.e. TmP/GFR, as a continuous variable. Our results reveal a strong heritable component of kidney stone disease in SFs with low TmP/GFR, suggesting that genetic factors play an important The number (n) of patients is indicated for each characteristic. Continuous variables are indicated by their mean 6 SD or by their median (25th-75th percentile). BSA, body surface area; NGIA, net gastrointestinal absorption. Models were calculated by mixed effects logistic regression and by mixed effects linear regression taking calendar day of blood sampling into account as a random effect. Univariable models for outcome variables listed contain TmP/GFR as the predictor variable. Multivariable models were adjusted for the covariables age, sex, BMI, GFR, diabetes and hypertension. The number of subjects in each model (n), the odds ratio (OR) or b coefficient and its 95% confidence interval (CI) and the P-value of the predictor variable are indicated. a Not adjusted for age. role in renal phosphate handling in SFs. Support for this notion comes from Mendelian forms of calcareous nephrolithiasis associated with sodium/phosphate co-transporter IIa and IIc gene mutations (SLC34A1 and SLC34A3, respectively) and recent genome-wide association studies and candidate gene sequencing both reported an association of sequence variants in the SLC34A1 gene with kidney stone disease [26] [27] [28] [29] . We failed to confirm previous reports of an association of FGF23 with TmP/GFR in SFs [12, 13] . The reason for this is not clear and may be due to different genetic backgrounds or diets (outpatient versus controlled) of patients studied [4, 12] . Another explanation may be the fact that we measured FGF23 with the second-generation C-terminal assay for FGF23, which detects both intact FGF23 and C-terminal fragments thereof and thus may overestimate 'bioactive' FGF23 [30, 31] . Hence it is possible that we missed an association of 'bioactive' intact FGF23 with TmP/GFR. However, a recent study using an intact FGF23 assay also failed to observe an association of FGF23 with fractional phosphate excretion in SFs [32] . Instead of FGF23, our multivariable regression analyses indicate that PTH, 25(OH)D and 1,25(OH) 2 D all showed a significant association with renal phosphate handling in SFs. The cause of increased PTH in SFs with phosphate leak cannot be deduced from our cross-sectional analysis. The finding that adjustment for the covariable 25(OH)D greatly attenuates the association of PTH with TmP/GFR suggests that low 25(OH)D 3 levels may drive a FIGURE 2: Visualization of selected multivariable regression models from Table 3 . All models were calculated by linear regression and are visualized using the R package visreg. Solid lines indicate regression lines and the shaped area represents the 95% confidence interval.
secondary PTH elevation and thus TmP/GFR reduction in SF. That this is indeed the case can only be confirmed by a prospective study.
Our analyses reveal that urinary calcium excretion is increased but 1,25(OH) 2 D decreased in SFs with low TmP/GFR. This suggests that not 1,25(OH) 2 D but other, as yet unidentified factors, are involved in the increase of urinary calcium excretion in the setting of low TmP/GFR. Interestingly, we also observed lower urinary oxalate excretion in SFs with renal phosphate leak, whereas urinary excretion of the metabolic oxalate precursor glycolate was unaltered, indicating that the difference may be caused by reduced gastrointestinal oxalate absorption or enhanced gastrointestinal oxalate secretion compared with SFs with high TmP/GFR. In line with these biochemical urinary alterations in SFs with low TmP/GFR, our results demonstrate for the first time an increased prevalence of brushite stones and a reduced prevalence of calcium oxalate stones in SFs with renal phosphate leak.
Chronic hypophosphataemia causes osteomalacia with elevated alkaline phosphatase and reduced BMD [33] . Our results are surprising in that they reveal no reduction of BMD and no alteration of alkaline phosphatase in SFs with low TmP/GFR. Together with our observation of elevated PTH in SFs with low TmP/GFR, these results may indicate the presence of a resistance to PTH action at the level of the bone. Clearly, measurements of not only total but bone-specific alkaline phosphatase FIGURE 3: Visualization of selected multivariable regression models from Table 4 . For dichotomous outcome variables, figures were created by an inverse logistic transformation of the linear regression line and 95% confidence intervals derived from the logistic regression models. The vertical axis for dichotomous outcome variables in logistic regression models is labelled with the probability scale and the horizontal axis with the predictor variable of interest.
Phosphate leak and kidney stones activity and of additional bone turnover markers are needed to further substantiate this claim.
A limitation of our study is the fact that we employed 24-h urinary phosphate for TmP/GFR estimations and not fasting spot urinary phosphate [34] . However, despite the random noise introduced by dietary variations when estimating TmP/GFR with 24-h urinary phosphate instead of fasting spot urine phosphate, it still remains a legitimate entity and has been widely used in the literature [35] [36] [37] [38] [39] [40] [41] . There is good agreement between spot and 24-h urinary phosphate-based TmP/GFR estimations [42] , indicating that 24-h urinary phosphate is a valid substitute for spot urinary phosphate for TmP/GFR estimations, especially in large patient cohorts as described in our study.
In conclusion, to our knowledge this is by far the largest study to date analysing the phenotype of SFs with respect to renal phosphate handling. Our results demonstrate that the clinical phenotype of reduced renal phosphate reabsorption in SFs has a strong heritable component and correlates with higher PTH, 25(OH)D and 1,25(OH) 2 D but not with FGF23 levels. Furthermore, our data reveal that stone formation with renal phosphate leak is associated with elevated urinary calcium and an increased prevalence of brushite stones.
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